Drug intelligence / Profile preview

Hb3 F(ab')2

Development stage
Unknown
Lead developer
MicroPharm
Modality
Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Hb3 F(ab')2 is a divalent antibody fragment derived from the Hb3 sheep monoclonal antibody, specifically developed for the treatment of envenomation by the European adder (*Vipera berus*). It is produced by the enzymatic digestion of whole IgG molecules obtained from sheep immunized with *Vipera berus* venom, followed by affinity purification. The F(ab')2 fragment contains two antigen-binding sites but lacks the Fc region, which reduces the risk of certain adverse immune reactions while maintaining a higher molecular weight than monovalent Fab fragments. This increased size results in a longer half-life in the systemic circulation, potentially offering better protection against the delayed absorption or recurrence of venom toxins. Its primary mechanism is the high-affinity binding and neutralization of venom components, including phospholipase A2 and other toxic proteins.

Other names
Sheep anti-Vipera berus F(ab')2Hb3 antibody fragmentHb-3 antibody fragmentHb 3 antibody fragment
02

Targets

PLA2 (Phospholipase A2 group IID)

Beyond the preview

Go deeper on Hb3 F(ab')2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hb3 F(ab')2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call